Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myeloid Malignancy: early-phase trial registry
7 of 8 indexed Myeloid Malignancy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 7 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Myeloid Malignancy: 8 US clinical trials tracked, 7 recruiting.
Myeloid Malignancy is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is University of Rochester, running 2 of these trials.
Enrollment posture brief
Registry condition myeloid-malignancy
OPEN 7 | RECR 88% | LATE 0 | EARLY 5 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Diseases (88% recruiting · 8 trials)
Myeloid Malignancy lists 7 open slots (88% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myeloid Malignancy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myeloid Malignancy is recruiting above its size-band peers.
7 of 8 indexed trials (87.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Myeloid Malignancy research.
University of Rochester accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Myeloid Malignancy trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Myeloid Malignancy research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Mayo Clinic
NCT02958462
A Telehealth Advance Care Planning Intervention
University of Rochester
NCT05875805
Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
University of Rochester
NCT07263074
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Masonic Cancer Center, University of Minnesota
NCT06594445
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Henry Ford Health System
NCT03850418
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Benjamin Tomlinson
NCT06129734
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
NCT07044544
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Jacqueline Garcia, MD
NCT05455294
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Myeloid Malignancy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myeloid Malignancy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myeloid Malignancy page
8 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Myeloid Malignancy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Rochester sponsors the most Myeloid Malignancy trials on record, review their full trial history before evaluating a specific study. See University of Rochester's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myeloid Malignancy condition card totals 8 registered trials; most-linked intervention Decitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.